QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer

This study is testing a combination immunotherapy called QL1706 in patients with advanced endometrial (uterine) cancer whose disease has progressed after PD-1/PD-L1 immunotherapy. It targets patients who initially responded well to immunotherapy but have since relapsed. **You may be eligible if...** - You are between 18 and 70 years old with advanced or recurrent endometrial cancer confirmed by pathology or imaging - You previously received PD-1/PD-L1 immunotherapy and had a progression-free period of at least 6 months - Your cancer is measurable on imaging - You have received no more than 2 prior lines of systemic therapy - Your general health is good (ECOG 0-1) and your organs are functioning adequately **You may NOT be eligible if...** - Your cancer is currently progressing while on immunotherapy (you must have had a gap of at least 5 drug half-lives since your last immunotherapy dose) - You have had more than 2 prior chemotherapy regimens Talk to your doctor to see if this trial is right for you.